IMPAX Laboratories, Inc. (IPXL.PK)
“Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995:
To the extent any statements made in this presentation contain information that is not
historical, these statements are forward-looking in nature and express the beliefs and
expectations of management. In particular, the forward-looking statements include
statements about IMPAX's estimated timelines and new application filing goals. Such
statements are based on current expectations and involve a number of known and unknown
risks and uncertainties that could cause Impax's future results, performance or achievements
to differ significantly from the results, performance or achievements expressed or implied by
such forward-looking statements. Such risks and uncertainties include, but are not limited to,
possible adverse effects resulting from the delisting of Impax's stock, Impax's delay in filing
its 2004 and 2005 Form 10-K’s and its Form 10-Q’s for the three quarters of 2005, Impax's
ability to obtain sufficient capital to fund its operations, the difficulty of predicting FDA filings
and approvals, consumer acceptance and demand for new pharmaceutical products, the
impact of competitive products and pricing, Impax's ability to successfully develop and
commercialize pharmaceutical products, Impax's reliance on key strategic alliances, the
uncertainty of patent litigation, the availability of raw materials, the regulatory environment,
dependence on patent and other protection for innovative products, exposure to product
liability claims, fluctuations in operating results and other risks detailed from time to time in
Impax's filings with the Securities and Exchange Commission. Forward-looking statements
speak only as to the date on which they are made, and Impax undertakes no obligation to
update publicly or revise any forward-looking statement, regardless of whether new
information becomes available, future developments occur or otherwise.
Note: All product sales data included herein are derived from data published by Wolters Kluwer
Health for the 12 months ending January 31, 2006, except for the veterinary product Carprofen,
which are derived from data published by Market Dynamics for the 12 months ending December
31, 2004.
Trademarks referenced herein are the property of their respective owners.
©2006 IMPAX Laboratories, Inc.
2
